The material came from some others in the 10 Comapnies list. The point was how many competitors are exploring similar pathways of efficacy. Good in that it verifies the pathways, bad in that is shows how much competition AVXL will have and how the glacial pace it has moved threatens to make it a laggard instead of a leader.